InSymbiosis works with a range of biopharma companies (virtual, small, and midsize) from around the world as well as large global pharma companies. The majority of our work is with human therapeutics companies and occasionally companies developing veterinary products.
As of 2019, InSymbiosis has worked on programs supporting over 120 therapeutic products covering small molecules, biologic drugs and more recently, cell-based therapies.
InSymbiosis specializes in the oversight of drug development programs and CRO management. Within this broad area we spend a lot of our time involved in candidate selection programs, non-clinical toxicology programs (supporting IND’s and NDA’s), formulation and CMC programs leading to GMP drug substance and drug product and clinical phase programs (Phases I, II and III).
We are indication agnostic and since our inception in 2005, we have worked on most of the main indications of interest to the pharma industry.
On June 12, 2019, InSymbiosis was acquired by Camargo.
Since 2005, InSymbiosis has proudly served pharma and biotech clients through a complete range of nonclinical and clinical capabilities, including lead optimization, efficacy studies, CMC, process development, regulatory toxicology, safety pharmacology and Phase I to III clinical development.
Together, under the Camargo name, we will continue to offer these services and more, including: